A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)-Reference-Cited by-同舟云学术

A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

Published:2023-03 Issue: Volume:181 Page:135-144
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ozaka Masato^ORCID,Nakachi Kohei,Kobayashi Satoshi^ORCID,Ohba Akihiro^ORCID,Imaoka Hiroshi,Terashima Takeshi,Ishii Hiroshi^ORCID,Mizusawa Junki,Katayama Hiroshi,Kataoka Tomoko^ORCID,Okusaka Takuji,Ikeda Masafumi^ORCID,Sasahira Naoki^ORCID,Miwa Haruo,Mizukoshi Eishiro,Okano Naohiro^ORCID,Mizuno Nobumasa^ORCID,Yamamoto Tomohisa^ORCID,Komatsu Yoshito,Todaka Akiko^ORCID,Kamata Ken,Furukawa Masayuki,Fujimori Nao^ORCID,Katanuma Akio^ORCID,Takayama Yukiko,Tsumura Hidetaka^ORCID,Fukuda Haruhiko^ORCID,Ueno Makoto,Furuse Junji

Funder

Japan Agency for Medical Research and Development

National Cancer Center Japan

Ministry of Health, Labour and Welfare

National Cancer Center

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Pancreatic cancer;Kamisawa;Lancet,2016

2. Pancreatic cancer;Vincent;Lancet,2011